Agenus Secures $22 Million Funding to Advance Immuno-Oncology Pipeline and Operational Efficiency

Agenus Secures Funding to Enhance Immuno-Oncology Pipeline

Agenus Inc., a Lexington-based immuno-oncology company, successfully closes a $22 million non-amortizing mortgage backed by its biomanufacturing facility in Berkeley and a 66-acre property in Vacaville, California. Facilitated by L&L Capital, this strategic financial move results in $20 million in net proceeds after accounting for closing costs and reserves. This infusion of capital significantly strengthens Agenus' cash position as the company anticipates additional cash inflows, allowing it to better navigate its ongoing operational realignment. The mortgage features a two-year term with a unique interest structure comprising 50% cash and 50% common stock, applying rates of 12% for the first year and 13% for the second.

In conjunction with securing this funding, Agenus implements a Strategic Operational Realignment Plan that focuses on its promising botensilimab/balstilimab (BOT/BAL) treatment for microsatellite-stable colorectal cancer (MSS CRC). The company aims for a 60% reduction in annual external expenditures, which includes the transition of its Chemistry, Manufacturing, and Controls (CMC) capabilities into a fee-for-service biologics manufacturing business. This realignment is designed to lower Agenus' fiscal year 2025 cash burn to approximately $100 million, pending further strategic transactions that could bolster its financial health. This operational shift reflects the company's commitment to enhancing efficiency while maintaining a strong focus on its core immuno-oncology products.

BOT/BAL has already exhibited remarkable efficacy in treating cancers that are resistant to current therapies, placing Agenus in a strong position for late-stage development and regulatory strategies aimed at both regional and global registrations. The encouraging clinical data supporting BOT/BAL across various treatment settings underscores its potential to transform care for patients with limited therapeutic options. Through this financial and operational restructuring, Agenus aims to not only innovate cancer treatment but also establish a robust foundation for future growth, ultimately benefiting patients who are in dire need of effective therapies.

In addition to its financial maneuvering and operational adjustments, Agenus remains dedicated to expanding its immunotherapy pipeline, which has been a hallmark of the company's mission since its inception in 1994. The company's commitment to advancing immuno-oncology through diverse therapeutic options continues to position it as a key player in the biopharmaceutical landscape. This ongoing focus on innovation and strategic alignment highlights Agenus' ambition to lead the way in developing transformative cancer treatments. For further details about its initiatives and products, Agenus encourages interested parties to visit their website at www.agenusbio.com.